KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Accumulated Expenses (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Accumulated Expenses data on record, last reported at $3.0 billion in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 6.55% year-over-year to $3.0 billion; the TTM value through Dec 2025 reached $3.0 billion, up 6.55%, while the annual FY2025 figure was $3.0 billion, 6.55% up from the prior year.
  • Accumulated Expenses reached $3.0 billion in Q4 2025 per VRTX's latest filing, down from $3.6 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $3.6 billion in Q3 2025 and bottomed at $1.5 billion in Q2 2021.
  • Average Accumulated Expenses over 5 years is $2.5 billion, with a median of $2.6 billion recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: dropped 6.97% in 2021, then soared 42.96% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $1.7 billion in 2021, then grew by 26.69% to $2.1 billion in 2022, then rose by 24.86% to $2.7 billion in 2023, then grew by 5.02% to $2.8 billion in 2024, then increased by 6.55% to $3.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $3.0 billion in Q4 2025, $3.6 billion in Q3 2025, and $3.3 billion in Q2 2025.